Dow Down1.29% Nasdaq Down3.25%

Oncothyreon Inc (ONTY)

1.15 Down 0.04(3.36%) 4:00PM EST
ProfileGet Profile for:
Oncothyreon Inc
2601 Fourth Avenue
Suite 500
Seattle, WA 98121
United States - Map
Phone: 206-801-2100
Fax: 206-801-2101

Index Membership:N/A
Full Time Employees:49

Business Summary 

Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, as well as certain types of lung cancer. The company is also developing Checkpoint kinase 1, a protein kinase in pre-clinical studies to inhibit tumor growth as single agents. In addition, it focuses on researching on Protocells, which are nanoparticles designed to enable the targeted delivery of various therapeutic agents, including nucleic acids, proteins, peptides, and small molecules, as well as to develop product candidates for the treatment of cancer and rare diseases. The company has a research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; collaboration with Celldex Therapeutics, Inc. on a combined clinical trial of ONT-10 and varlilumab; and collaboration with Adimab LLC for the discovery of novel antibodies against undisclosed immunotherapy targets in oncology. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Oncothyreon Inc

Corporate Governance 
Oncothyreon Inc’s ISS Governance QuickScore as of Feb 1, 2016 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 6.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Christopher S. Henney B.Sc. (Hons.), Ph.D., D.Sc., 75
Chairman, Interim Chief Exec. Officer, Interim Pres, Chairman of Corp. Governance & Nominating Committee and Member of Compensation Committee
Ms. Julia M. Eastland M.B.A., 52
Chief Financial Officer, Principal Accounting Officer, VP of Corp. Devel. and Sec.
Mr. Gary Christianson PE, 61
Chief Operating Officer
Dr. Scott Robert Peterson Ph.D., 54
Chief Scientific Officer
Dr. Diana F. Hausman M.D., 53
Chief Medical Officer
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders